Monoclonal Antibody Therapy: Infusion Reactions, Hypersensitivity, and Management

An infusion reaction is a broad term that includes any adverse reaction occurring during or shortly after the infusion. The most common type is cytokine release syndrome (CRS), which is not allergic but rather a result of immune cell activation and cytokine release. Symptoms include fever, chills, rigors, and nausea. An allergic reaction, specifically IgE-mediated anaphylaxis, involves the immune system producing specific IgE antibodies against the monoclonal antibody. Symptoms include urticaria, angioedema, wheezing, and hypotension. The distinction is critical because management differs: infusion reactions are managed by slowing the rate and premedicating, while IgE-mediated reactions require desensitization or alternative therapy. An allergist can help determine the mechanism through skin testing and clinical history.

Yes, IgE-mediated allergy to monoclonal antibodies typically develops after multiple uneventful doses, not on the first exposure. This is because the immune system requires time to recognize the monoclonal antibody as foreign and produce specific IgE antibodies. This is in contrast to cytokine release syndrome, which is most common on the first dose. The risk of developing IgE-mediated allergy is higher with chimeric antibodies (containing mouse protein sequences, e.g., infliximab, rituximab) than with fully humanized antibodies. If you have received multiple doses without issue and then develop symptoms like hives, swelling, or wheezing during a subsequent infusion, this pattern is more suggestive of an IgE-mediated reaction and should be evaluated by an allergist.

Having other allergies (e.g., to pollen, foods, or medications) does not necessarily mean you will react to a monoclonal antibody. However, a history of drug allergies or severe allergic reactions may increase your overall risk and warrants closer monitoring. Patients with asthma, particularly if poorly controlled, may be at higher risk for more severe reactions if they do occur. It is important to inform your healthcare provider about all your allergies before starting monoclonal antibody therapy. Your doctor may recommend premedication, a slower infusion rate, or additional monitoring based on your allergy history. An allergist can help assess your individual risk and develop a personalized management plan.

If you experience any symptoms during the infusion, tell your healthcare team immediately. Do not wait to see if the symptoms will go away on their own. Early intervention is key to preventing a mild reaction from becoming severe. Your healthcare team will stop the infusion, assess your symptoms, and provide appropriate treatment. For mild symptoms (e.g., mild flushing, headache), they may give you antihistamines and restart the infusion at a slower rate. For moderate to severe symptoms (e.g., hives, wheezing, hypotension), they will treat the reaction with epinephrine, antihistamines, and corticosteroids as needed. After the reaction is controlled, your allergist can help determine the best approach for future infusions.

A desensitization protocol typically takes 4 to 12 hours, depending on the specific monoclonal antibody, the patient's reaction history, and the protocol used. The process involves administering 12–16 incremental doses, starting with a very dilute concentration and doubling every 15–30 minutes until the full therapeutic dose is reached. The patient is monitored closely throughout the procedure, with vital signs checked frequently and emergency medications readily available. Desensitization must be repeated for each subsequent infusion, as the tolerance induced is temporary and wanes within days. While the time commitment is significant, it allows over 90% of patients to safely receive their therapy.

No, monoclonal antibody therapy should not be administered at home if you have a history of a significant reaction. Infusions should be given in a healthcare setting equipped to manage severe allergic reactions, such as a hospital infusion center, a clinic with emergency medications, or an intensive care unit for desensitization protocols. The setting should have immediate access to epinephrine, oxygen, intravenous fluids, and personnel trained in managing anaphylaxis. Even with premedication and a slow infusion rate, there is always a risk of a reaction. For patients undergoing desensitization, the procedure is typically performed in an ICU or specialized unit with continuous monitoring.

The success rate of desensitization for monoclonal antibody hypersensitivity is over 90% in published clinical studies. Success is defined as the patient completing the full therapeutic dose without a severe reaction. Most patients (80–90%) experience either no reaction or only mild breakthrough symptoms (e.g., mild urticaria, flushing) that are easily managed with antihistamines and do not require stopping the infusion. Severe breakthrough reactions requiring epinephrine occur in less than 5% of desensitizations. The high success rate makes desensitization the standard of care for patients who have experienced a significant reaction and need to continue their therapy.

Yes, fully human monoclonal antibodies are generally less immunogenic than chimeric (part mouse, part human) or murine (fully mouse) antibodies. Chimeric antibodies, such as infliximab and rituximab, contain mouse protein sequences that are more likely to be recognized as foreign by the human immune system, increasing the risk of IgE-mediated reactions. Fully human antibodies, such as adalimumab and golimumab, are engineered to contain only human protein sequences, which reduces but does not eliminate the risk of allergic reactions. Even fully human antibodies can cause reactions, particularly infusion reactions mediated by cytokine release or other non-IgE mechanisms. The risk of IgE-mediated reactions is lower but not zero.

Yes, delayed allergic reactions to monoclonal antibodies can occur, though they are less common than immediate reactions. The most common delayed reaction is serum sickness-like reaction, which typically occurs 1–14 days after the infusion. Symptoms include rash (often urticarial or morbilliform), arthralgias (joint pain), fever, and lymphadenopathy. This reaction is mediated by immune complex deposition rather than IgE. Other delayed reactions include delayed urticaria, maculopapular rash, and, rarely, severe cutaneous adverse reactions such as Stevens-Johnson syndrome or drug reaction with eosinophilia and systemic symptoms (DRESS). Delayed reactions are managed with antihistamines and corticosteroids, and the monoclonal antibody may need to be discontinued if the reaction is severe.

For patients who cannot undergo skin testing (e.g., due to dermatographism, severe eczema, or inability to discontinue antihistamines), alternative diagnostic approaches are available. The most important is a detailed clinical history, including the timing, symptoms, and severity of the reaction. Serum tryptase levels drawn during or shortly after the reaction can support the diagnosis of anaphylaxis. In vitro specific IgE testing is available for some monoclonal antibodies through specialized reference laboratories. A graded challenge, where the patient receives increasing doses of the monoclonal antibody under close monitoring, can also be used to assess tolerance. In some cases, the diagnosis is made clinically, and the patient proceeds directly to a desensitization protocol if continued therapy is necessary.